FDA
-
-
-
-
-
-
-
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
-
-
-
-
-
-
-
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
-
-
323,751 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

